Milestone Scient (MLSS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 4, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MLSS SEC filings page.
Milestone Scient (MLSS) reported $9.4M in revenue over the twelve months to Jun 30, 2026, up 3.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Accounting earnings are positive, but the business remains an operating-loss enterprise financed through a thinner equity base.
In FY2025, net income was$5.7M while the operating loss was$5.7M . Operating cash flow was-$2.9M , and the same profit/cash disconnect appeared in FY2024, pointing to below-operating-line effects rather than cash-generating operations.
Gross margin remained
Debt-to-equity rose to 1.8x as equity fell to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Milestone Scient's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Milestone Scient has an operating margin of -63.5%, meaning the company loses $63 on every $100 of revenue. This results in a profitability score of 28/100. This is up from -78.3% the prior year.
Milestone Scient's revenue grew a modest 4.0% year-over-year to $9.0M. This slow but positive growth earns a score of 18/100.
Milestone Scient has a moderate D/E ratio of 1.78. This balance of debt and equity financing earns a leverage score of 34/100.
Milestone Scient's current ratio of 1.81 indicates adequate short-term liquidity, earning a score of 53/100. The company can meet its near-term obligations, though with limited headroom.
Milestone Scient's operations used $2.9M of cash, and capex of $15K added to the outflow, for a free cash flow shortfall of $2.9M. This results in a cash flow score of 7/100.
Milestone Scient generates a 203.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 20/100. This is up from 80.8% the prior year.
Milestone Scient scores -19.74, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($41.6M) relative to total liabilities ($5.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Milestone Scient passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Milestone Scient used $0.51 of operating cash (-$2.9M OCF vs $5.7M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Milestone Scient reported an operating loss of $5.7M against $26K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Milestone Scient generated $2.8M in revenue in Q2 2026. This represents an increase of 22.3% from the same quarter a year earlier. Against the prior quarter it is up 31.4%.
Milestone Scient's EBITDA was -$1.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 28.9% from the same quarter a year earlier. Against the prior quarter it is down 28.9%.
Milestone Scient reported -$1.1M in net income in Q2 2026. This represents an increase of 28.6% from the same quarter a year earlier. Against the prior quarter it is down 26.1%.
Milestone Scient earned -$0.01 per diluted share (EPS) in Q2 2026. This represents an increase of 50.0% from the same quarter a year earlier. It is unchanged from the prior quarter.
Cash & Balance Sheet
Milestone Scient recorded an outflow of $589K in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 66.7% from the same quarter a year earlier. Against the prior quarter it is down 791.5%.
Milestone Scient held $2.1M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Milestone Scient's gross margin was 67.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 2.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.1 percentage points.
Milestone Scient's operating margin was -37.4% in Q2 2026, reflecting core business profitability. This is up 26.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.9 percentage points.
Milestone Scient's net profit margin was -37.3% in Q2 2026, showing the share of revenue converted to profit. This is up 26.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.6 percentage points.
Milestone Scient's ROE was -30.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 13.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.2 percentage points.
Capital Allocation
Milestone Scient invested $7K in research and development in Q2 2026. This represents a decrease of 87.2% from the same quarter a year earlier.
Milestone Scient invested $4K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 7.4% from the same quarter a year earlier. Against the prior quarter it is up 153.6%.
Not reported for Q2 2026.
MLSS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M+22.3% | $2.2M-3.2% | $2.1M+2.2% | $2.4M-6.1% | $2.3M+25.3% | $2.2M-0.7% | $2.0M-10.9% | $2.5M+22.1% |
| Cost of Revenue | $931K+31.9% | $598K+2.2% | $556K+10.7% | $719K+6.1% | $706K+59.5% | $585K+2.1% | $502K-33.1% | $678K+21.9% |
| Gross Profit | $1.9M+18.1% | $1.6M-5.1% | $1.5M-0.6% | $1.6M-10.6% | $1.6M+14.6% | $1.6M-1.7% | $1.5M+0.1% | $1.8M+22.1% |
| R&D Expenses | $7K-87.2% | N/A | $12K-94.3% | $16K-93.0% | $52K-83.6% | $369K+291.8% | $218K+23.0% | $232K+36.1% |
| SG&A Expenses | $2.9M-2.8% | $2.4M-27.1% | $2.5M-23.4% | $2.7M-10.6% | $3.0M+5.7% | $3.3M+7.3% | $3.3M+0.8% | $3.1M+8.5% |
| Operating Income | -$1.1M+28.5% | -$828K+58.6% | -$1.1M+47.1% | -$1.1M+22.8% | -$1.5M+16.6% | -$2.0M-36.4% | -$2.0M-3.2% | -$1.5M+2.5% |
| EBITDA | -$1.0M+28.9% | -$809K+59.1% | -$1.1M+47.9% | -$1.1M+23.7% | -$1.5M+17.3% | -$2.0M-36.1% | -$2.0M-3.4% | -$1.5M+2.0% |
| Interest Expense | N/A | $12K+260.3% | N/A | $19K+143.4% | $2K-92.7% | $3K-86.7% | $7K-70.5% | $8K-73.8% |
| Income Tax | N/A | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Net Income | -$1.1M+28.6% | -$840K+57.9% | $10.4M+40.1% | -$1.2M+21.0% | -$1.5M-763.2% | -$2.0M-38.5% | $7.4M-38.0% | -$1.5M+0.3% |
| EPS (Basic) | -$0.01+50.0% | -$0.01+50.0% | -$0.01+66.7% | -$0.01+50.0% | -$0.02 | -$0.020.0% | -$0.030.0% | -$0.020.0% |
| EPS (Diluted) | -$0.01+50.0% | -$0.01+50.0% | -$0.01+66.7% | -$0.01 | -$0.02 | -$0.02 | -$0.03 | -$0.02 |
| Diluted Shares (Avg) | 93M+13.5% | 85M+3.9% | N/A | 82M | 82M+2.6% | 82M | N/A | 80M |
MLSS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.3M+3.7% | $8.0M-12.4% | $7.8M-20.3% | $8.5M-24.1% | $8.1M-32.9% | $9.1M-19.9% | $9.8M-13.8% | $11.2M-1.7% |
| Current Assets | $8.1M+6.4% | $7.4M-14.8% | $7.5M-19.5% | $8.1M-24.2% | $7.6M-33.6% | $8.6M-20.2% | $9.3M-14.0% | $10.7M+7.3% |
| Cash & Equivalents | $2.1M+62.2% | $1.2M-46.6% | $1.1M-66.2% | $1.3M-71.8% | $1.3M-77.8% | $2.2M-43.9% | $3.3M+9.4% | $4.8M+120.0% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $0-100.0% | $0-100.0% |
| Inventory | $3.1M-20.8% | $3.5M-16.1% | $3.8M+1.8% | $4.1M+11.2% | $3.9M+17.1% | $4.2M+45.4% | $3.7M+40.7% | $3.7M+49.5% |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | $475K+52.0% | $551K-6.8% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4.9M+3.5% | $5.7M+22.8% | $5.0M+26.0% | $5.9M+50.2% | $4.7M+16.3% | $4.6M+18.9% | $4.0M+18.0% | $4.0M+10.1% |
| Current Liabilities | $4.4M+16.7% | $4.9M+9.3% | $4.1M+10.3% | $5.0M+33.9% | $3.8M-1.5% | $4.4M+22.2% | $3.7M+21.7% | $3.8M+14.6% |
| Non-Current Liabilities | $480K-49.1% | $821K+351.0% | $863K+291.6% | $903K+361.6% | $943K+319.0% | $182K-28.3% | $220K-22.0% | $196K-37.2% |
| Total Equity | $3.5M+3.9% | $2.3M-48.8% | $2.8M-51.8% | $2.5M-64.7% | $3.3M-58.0% | $4.5M-40.2% | $5.8M-27.2% | $7.2M-0.3% |
| Retained Earnings | -$135.7M-3.2% | -$134.6M-3.5% | -$133.8M-4.5% | -$132.7M-5.3% | -$131.5M-5.6% | -$130.0M-4.2% | -$128.1M-3.8% | -$126.0M-3.8% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
MLSS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$585K+66.8% | $87K+108.6% | -$226K+85.0% | $82K+108.4% | -$1.8M-325.1% | -$1.0M+17.2% | -$1.5M-21.3% | -$974K+7.5% |
| Depreciation & Amortization | $20K+0.5% | $19K+0.1% | $19K+119.8% | $20K+134.5% | $19K+130.0% | $19K+66.4% | $9K-28.1% | $9K-46.1% |
| Stock-Based Compensation | N/A | $257K-22.4% | N/A | N/A | $160K-23.1% | $331K+5.5% | N/A | N/A |
| Capital Expenditures | $4K-7.4% | $2K+25.2% | $3K-11.7% | $6K | $4K | $1K | $4K | N/A |
| Free Cash Flow | -$589K+66.7% | $85K+108.4% | -$229K+84.9% | $76K | -$1.8M | -$1.0M | -$1.5M | N/A |
| Investing Cash Flow | -$4K+7.4% | -$2K-25.2% | -$3K+11.7% | -$6K | -$4K-100.5% | -$1K-100.1% | -$4K+99.3% | $0+100.0% |
| Financing Cash Flow | $1.5M+83.5% | -$3K-50.5% | -$3K-35.3% | -$5K-75.6% | $797K+31461.5% | -$2K-100.9% | -$3K-100.1% | -$3K-20.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
MLSS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.2%-2.4pp | 72.3%-1.5pp | 73.0%-2.1pp | 69.5%-3.5pp | 69.6%-6.5pp | 73.8%-0.7pp | 75.0%+8.3pp | 73.0%0.0pp |
| Operating Margin | -37.4%+26.5pp | -38.3%+51.2pp | -52.5% | -48.1%+10.4pp | -63.9%+32.1pp | -89.5%-24.3pp | -101.4% | -58.4%+14.7pp |
| Net Margin | -37.3%+26.5pp | -38.9%+50.5pp | 503.1% | -48.9%+9.2pp | -63.8%-75.9pp | -89.3%-25.3pp | 367.1% | -58.1%+13.1pp |
| Return on Equity | -30.5%+13.9pp | -36.8%+7.9pp | 368.1%+241.4pp | -45.3%-25.0pp | -44.4%-47.2pp | -44.7%-25.4pp | 126.7%-22.0pp | -20.2%0.0pp |
| Return on Assets | -12.7%+5.7pp | -10.5%+11.4pp | 132.6%+57.2pp | -13.6%-0.5pp | -18.4%-20.3pp | -21.9%-9.3pp | 75.4%-29.4pp | -13.1%-0.2pp |
| Current Ratio | 1.85-0.2x | 1.51-0.4x | 1.81-0.7x | 1.61-1.2x | 2.03-1.0x | 1.94-1.0x | 2.48-1.0x | 2.85-0.2x |
| Debt-to-Equity | 1.410.0x | 2.48+1.4x | 1.78+1.1x | 2.33+1.8x | 1.41+0.9x | 1.04+0.5x | 0.68+0.3x | 0.55+0.1x |
| Asset Turnover | 0.34+0.1x | 0.270.0x | 0.26+0.1x | 0.28+0.1x | 0.29+0.1x | 0.250.0x | 0.210.0x | 0.230.0x |
| FCF Margin | -20.7%+55.4pp | 3.9%+49.2pp | -11.1%+64.1pp | 3.2% | -76.1% | -45.2% | -75.2% | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Milestone Scient MLSS | FY2025 | $9.0M | $5.7M | 63.8% | $41.6M | 27/100 |
| Nephros Inc NEPH | FY2025 | $18.8M | $1.2M | 6.3% | $44.1M | 53/100 |
| Precision Optics POCI | FY2025 | $19.1M | -$5.8M | -30.3% | $47.6M | 26/100 |
| Retractable Tech RVP | FY2025 | $38.3M | -$12.6M | -32.8% | $21.4M | 24/100 |
| Harvard Biosci HBIO | FY2025 | $86.5M | -$56.7M | -65.5% | $36.5M | 38/100 |
| Nexgel Inc NXGL | FY2025 | $11.4M | -$3.0M | -26.3% | $3.1M | 37/100 |
Where Milestone Scient Ranks
Frequently Asked Questions
What is Milestone Scient's annual revenue?
Milestone Scient (MLSS) reported $9.0M in total revenue for fiscal year 2025. This represents a 4.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Milestone Scient's revenue growing?
Milestone Scient (MLSS) revenue grew by 4.0% year-over-year, from $8.6M to $9.0M in fiscal year 2025.
Is Milestone Scient profitable?
Yes, Milestone Scient (MLSS) reported a net income of $5.7M in fiscal year 2025, with a net profit margin of 63.8%.
What is Milestone Scient's EBITDA?
Milestone Scient (MLSS) had EBITDA of -$5.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Milestone Scient's gross margin?
Milestone Scient (MLSS) had a gross margin of 71.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Milestone Scient's operating margin?
Milestone Scient (MLSS) had an operating margin of -63.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Milestone Scient's net profit margin?
Milestone Scient (MLSS) had a net profit margin of 63.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Milestone Scient's return on equity (ROE)?
Milestone Scient (MLSS) has a return on equity of 203.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Milestone Scient's free cash flow?
Milestone Scient (MLSS) recorded an outflow of $2.9M in free cash flow during fiscal year 2025. This represents a -0.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Milestone Scient's operating cash flow?
Milestone Scient (MLSS) recorded an outflow of $2.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Milestone Scient's total assets?
Milestone Scient (MLSS) had $7.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Milestone Scient's capital expenditures?
Milestone Scient (MLSS) invested $15K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Milestone Scient spend on research and development?
Milestone Scient (MLSS) invested $449K in research and development during fiscal year 2025.
What is Milestone Scient's current ratio?
Milestone Scient (MLSS) had a current ratio of 1.81 as of fiscal year 2025, which is generally considered healthy.
What is Milestone Scient's debt-to-equity ratio?
Milestone Scient (MLSS) had a debt-to-equity ratio of 1.78 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Milestone Scient's return on assets (ROA)?
Milestone Scient (MLSS) had a return on assets of 73.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Milestone Scient's P/E ratio?
Milestone Scient (MLSS) trades at 5.7x earnings, its market capitalization divided by net income of $7.3M net income, trailing 12 months to June 30, 2026. The market capitalization is $41.6M as of Sep 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Milestone Scient's price-to-sales ratio?
Milestone Scient (MLSS) trades at 4.4x sales, its market capitalization divided by revenue of $9.4M revenue, trailing 12 months to June 30, 2026. The market capitalization is $41.6M as of Sep 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Milestone Scient's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Milestone Scient (MLSS) held $1.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $2.9M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Milestone Scient's Altman Z-Score?
Milestone Scient (MLSS) has an Altman Z-Score of -19.74, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Milestone Scient's Piotroski F-Score?
Milestone Scient (MLSS) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Milestone Scient's earnings high quality?
For every $1 of reported earnings, Milestone Scient (MLSS) used $0.51 of operating cash (-$2.9M OCF vs $5.7M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Milestone Scient cover its interest payments?
Milestone Scient (MLSS) reported an operating loss of $5.7M against $26K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Milestone Scient?
Milestone Scient (MLSS) scores 27 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.